Other Analyses or Reports Sample Clauses

Other Analyses or Reports. ETS will partner with the CDE and SBE staff/liaisons to identify and expand on research questions and develop instruments for CDE’s approval. Together, ETS will make recommendations for all data collection instruments, such as interview protocols, observation protocols, surveys, and cognitive labs. ETS will then deliver the instruments within the test delivery system in order to link responses to student performance and student demographic data from CALPADS. Studies to be included are: Analytic research on the impact of AI scoring at the sub-group level to determine if any group is disadvantaged by the new technology. Statistical analysis of the necessary N size and aggregation of sub-claim score for assessments at the LEA level. Efficacy or impact of extended response items types as a tool to provide professional development in both summative scoring modality and various interim scoring situations. Effect(s) of any universal tools, designated supports, and/or accommodations used by students (particularly students with disabilities and English learners) on the CAA. Once each year during the term of the contract with the CDE, ETS will propose additional studies and analyses to support the validity of the CAASPP program, evaluate new initiatives, or address relevant policy issues. ETS will recommend additional studies either proactively or upon request. ETS will work with the CDE to support the technical quality of the CAASPP System, which includes validity, reliability, fairness and accessibility, and comparability. A global view of the process would be that ETS and the CDE and SBE staff and liaisons would meet at least once a year to discuss special studies. Should CDE request any special studies, ETS will meet with researchers who have specific expertise in the study area requested. ETS would present the research study plans, along with a statement of cost, to the CDE. Together, the CDE, SBE staff and liaisons, and ETS staff would discuss the specific plans and make necessary modifications before agreeing on final costs. All special studies and research will adhere to the requirements outlined in Appendix B, Reporting Expectations for Special Studies and Research Projects.
Sample 1
AutoNDA by SimpleDocs

Related to Other Analyses or Reports

  • Other Reports (a) Promptly upon receipt thereof, copies of all reports, if any, submitted to the Borrower or its Board of Directors by its independent public accountants in connection with their auditing function, including, without limitation, any management report and any management responses thereto; and

  • Reports The Depositary shall make available for inspection by Owners at its Office any reports and communications, including any proxy solicitation material, received from the Company which are both (a) received by the Depositary as the holder of the Deposited Securities and (b) made generally available to the holders of those Deposited Securities by the Company. The Company shall furnish reports and communications, including any proxy soliciting material to which this Section applies, to the Depositary in English, to the extent those materials are required to be translated into English pursuant to any regulations of the Commission.

  • Progress Reports The Recipient shall submit to the OPWC, at the OPWC's request, summary reports detailing the progress of the Project pursuant to this Agreement and any additional reports containing such information as the OPWC may reasonably require.

  • Daily Job Reports 6.7.2.1 Developer shall maintain, at a minimum, at least one (1) set of Daily Job Reports on the Project. These must be prepared by Xxxxxxxxx's employee(s) who are present on Site, and must include, at a minimum, the following information:

  • Analyses investigations, surveys and reports described in Section 5 above as Reimbursable Services;

  • Evaluation Reports Where a formal evaluation of an employee's performance is carried out, the employee shall be provided with a copy to read and review. Provision shall be made on the evaluation form for an employee to sign it. The form shall provide for the employee's signature in two (2) places, one indicating that the employee has read and accepts the evaluation, and the other indicating that the employee disagrees with the evaluation. The employee shall sign in one of the places provided within seven (7) calendar days. No employee may initiate a grievance regarding the contents of an evaluation report unless the signature indicates disagreement with the evaluation. The employee shall receive a copy of the evaluation report at the time of signing. An evaluation report shall not be changed after an employee has signed it, without the knowledge of the employee, and any such changes shall be subject to the grievance procedure.

  • Other Reporting Upon request, the School shall provide the Commission any other information determined by the Commission to be relevant to any term or condition of this Contract.

  • Technical Reports deliver to the Agent, and shall procure that the Manager shall deliver to the Agent, on request copies of the latest complete technical reports in respect of the Vessels.

  • Status Reports DSI will issue to Depositor and Preferred Beneficiary a report profiling the account history at least semi-annually. DSI may provide copies of the account history pertaining to this Agreement upon the request of any party to this Agreement.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

Time is Money Join Law Insider Premium to draft better contracts faster.